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Abstract
Background: Although ZnO nanoparticles (NPs) are used in many commercial products and the potential for
human exposure is increasing, few in vivo studies have addressed their possible toxic effects after inhalation. We
sought to determine whether ZnO NPs induce pulmonary toxicity in mice following sub-acute or sub-chronic
inhalation exposure to realistic exposure doses.
Methods: Mice (C57Bl/6) were exposed to well-characterized ZnO NPs (3.5 mg/m3, 4 hr/day) for 2 (sub-acute) or
13 (sub-chronic) weeks and necropsied immediately (0 wk) or 3 weeks (3 wks) post exposure. Toxicity was assessed
by enumeration of total and differential cells, determination of total protein, lactate dehydrogenase activity and
inflammatory cytokines in bronchoalveolar lavage (BAL) fluid as well as measurements of pulmonary mechanics.
Generation of reactive oxygen species was assessed in the lungs. Lungs were evaluated for histopathologic changes
and Zn content. Zn concentration in blood, liver, kidney, spleen, heart, brain and BAL fluid was measured.
Results: An elevated concentration of Zn2+ was detected in BAL fluid immediately after exposures, but returned
to baseline levels 3 wks post exposure. Dissolution studies showed that ZnO NPs readily dissolved in artificial
lysosomal fluid (pH 4.5), but formed aggregates and precipitates in artificial interstitial fluid (pH 7.4). Sub-acute
exposure to ZnO NPs caused an increase of macrophages in BAL fluid and a moderate increase in IL-12(p40) and
MIP-1α, but no other inflammatory or toxic responses were observed. Following both sub-acute and sub-chronic
exposures, pulmonary mechanics were no different than sham-exposed animals.
Conclusions: Our ZnO NP inhalation studies showed minimal pulmonary inflammation, cytotoxicity or lung
histopathologic changes. An elevated concentration of Zn in the lung and BAL fluid indicates dissolution of ZnO
NPs in the respiratory system after inhalation. Exposure concentration, exposure mode and time post exposure
played an important role in the toxicity of ZnO NPs. Exposure for 13 wks with a cumulative dose of 10.9 mg/kg
yielded increased lung cellularity, but other markers of toxicity did not differ from sham-exposed animals, leading to
the conclusion that ZnO NPs have low sub-chronic toxicity by the inhalation route.
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Introduction
Materials engineered at the nanoscale currently exist in
over a thousand consumer products including cosmetics,
electronics, medical devices, and textiles [1]. Metal and
metal oxide nanoparticles (NPs) are also under develop-
ment for antimicrobial, self-decontaminating and UV
blocking functions for both military protection gear and
civilian health products. Ag, TiO2, ZnO, and CeO2 are
among the nanomaterials most widely incorporated
into market goods. Zinc oxide (ZnO) NPs are used in
various product categories because of their unique
photocatalytic, electronic, optical, dermatological, and
antibacterial properties; however the most common
applications are in sunscreens [2], baby powders, anti-
dandruff shampoos, and fabric treatments for UV shield-
ing [3,4]. Welding fumes, especially from galvanized
steel, can also be source of exposure to ZnO aerosol in
the nanometer range [5,6]. Additionally, ZnO NPs have
received more attention due to their putative anti-cancer
properties and for drug delivery [7].
Most of the production processing takes place within
closed systems, however during postproduction and
packaging, ZnO NPs may be released into the ambient
air where they circulate for some time. During this time
there is a potential for worker and public exposure via
inhalation [2]. With increasing interest to their potential
toxicity, adverse effects of ZnO NPs have been recently
studied in vivo [8-13] and in vitro [14-21]. However, des-
pite the growing literature on nanomaterials applica-
tions, the information about biological effects of ZnO
NPs is still insufficient and often controversial. Many re-
ports using in vitro systems indicate that the mechanism
of ZnO toxicity involves the generation of reactive oxy-
gen species (ROS) [15,16,18,22]. Some report that dissol-
ution of ZnO, which is enhanced for the smallest
particles [23] plays an important role in the toxicity
mechanism of ZnO NPs [18,19,22]. It has been shown
that ZnO dissociation disrupts cellular zinc homeostasis
in mouse leukemic monocyte macrophage cells (RAW
264.7), leading to lysosomal and mitochondria damage
and ultimately cell death [22]. Another in vitro study in-
dicated that free Zn2+ ions are not a major contributor
of ROS generation [16]. The release of ions from ZnO
NPs in biological media depends on many factors, such
as pH, ligands present in the solution, surface groups, or
impurities [11]. Because of these effects, it can be lower
or higher than predicted from aqueous phase thermo-
dynamic behavior of ZnO alone [18]. A limitation of the
above-referenced studies is that the nanoparticle dose
used usually exceeds an environmentally relevant dose.
Moreover, these in vitro models cannot replicate the in-
tact cardiovascular system and various cellular interac-
tions present in the body. Hence, in vitro models fall
short of accurately predicting the toxicological behavior
of the nanoparticles in living organisms, especially if
studied in submersed conditions when particles are sus-
pended in media [24] which can impact dispersion and
dissolution.
More recently, there is an increasing body of literature
reporting on ZnO NP toxicity studies in vivo [8-12,25].
An oral exposure of mice to 20 and 120 nm particles in-
dicated minimal toxicity of ZnO NPs, where smaller
NPs were slightly more toxic than the larger ones [9].
Some pathological damage was observed in gastric, liver,
heart and spleen in this oral toxicity study. Pulmonary
toxicity has been assessed in instillation [8,11,12,26]
and inhalation exposure [10] models. Instillation studies
in rodents have shown that ZnO NPs are capable of
inducing acute pulmonary inflammation, including neu-
trophil recruitment and lactate dehydrogenase (LDH) re-
lease at cumulative doses of 0.6 mg/kg [11] and 5 mg/kg
[12]. Moreover, it has been suggested that metal oxide
NPs may produce unique inflammatory footprints in the
lung depending on the metal content and a propensity
to deliver soluble ions [8]. ZnO NPs exhibited eosino-
philic inflammation without cytotoxicity in the rat instil-
lation exposure study by Cho et al. [8]. A decreased
dissolution of ZnO NPs by iron doping reduced pulmon-
ary inflammation in another oropharyngeal and intratra-
cheal instillation rat study [11].
In order to better understand, and potentially resolve,
disparate findings from in vivo instillation studies and
in vitro studies, we exposed male C57Bl/6 mice to fully
characterized commercially available ZnO NPs by inhal-
ation in a whole-body inhalation chamber for periods of
2 or 13 wks. The potential toxic effects associated with
the inhalation of ZnO NPs were assessed in mice with
evaluation of lung inflammation, cytotoxicity, oxidative
stress, pulmonary mechanics with methacholine chal-
lenge and hematology parameters. Body burden of zinc
in the lungs, blood and other selected tissues was
measured.
Materials and methods
Nanomaterial bulk properties characterization
Zinc oxide NPs with stated primary particle average
diameter of 10 nm were purchased in two different lots
(Meliorum Technologies, Inc. Rochester, NY) and used
as received. Powder X-ray diffraction (XRD) was per-
formed using Bruker D-5000 q – q X-ray diffractom-
eter with Kevex-sensitive detector (Madison, WI) to
identify crystalline phases present in the sample. We
assessed the primary particle size of 400 random ZnO
NPs by transmission electron microscopy (TEM)
(JEOL JEM-1230, Japan) to evaluate the veracity of the
manufacturer’s specifications, as well as to image the
NPs aerosols generated in the inhalation exposure
chamber.
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Surface area and surface composition of the ZnO NPs
were measured. For surface area measurements, an auto-
mated multipoint BET surface area apparatus (Quanta-
chrome Nova 4200e, Boynton Beach, FL) using nitrogen
gas as the adsorbent was used. Samples were degassed at
100°C for 12 hr under vacuum prior to the analysis. Sur-
face composition was characterized using attenuated total
reflectance (ATR) Fourier transform infrared (FTIR) spec-
troscopy equipped with a MCT/A detector (Thermo Sci-
entific Nicolete FTIR spectrometer, Waltham, MA). For
these measurements, a thin, evenly coated ZnO film was
deposited onto an AMTIR (amorphous material transmit-
ting infrared radiation) crystal element in a horizontal ATR
cell (Pike Technologies, Inc.). The film was prepared by
placing a suspension of ZnO NPs (1 mg/mL in Optima
water) onto the crystal and drying overnight. X-ray photo-
electron spectroscopy (XPS) was used to probe the surface
chemical composition of the powdered sample (Ultra-Axis
XPS, Kratos, Manchester, UK) as previously described [27].
Dissolution measurements
Dissolution of ZnO NPs was measured in simulated bio-
logical fluids including artificial lysosomal fluid (ALF)
(pH = 4.5) and Gamble’s solution (pH = 7.4) using in-
ductively coupled plasma optical emission spectroscopy
(ICP-OES) (Varian 720 ES, Walnut Creek, CA) as previ-
ously described [28]. The ALF fluid simulates the phago-
lysosomal composition and pH of alveolar and interstitial
macrophages and the Gamble’s solution is used to mimic
the interstitial fluid in the lungs.
Animals
Inhalation exposure studies followed the same experimen-
tal design as in several of our previous studies [28-30].
Mice (C57Bl/6, males, 5 wks old, The Jackson Laboratory,
Bar Harbor, ME) were acclimatized for 12 days before ex-
posure while housed in our vivarium in polypropylene,
fiber-covered cages in HEPA-filtered Thoren caging units
(Hazelton, PA). Food (sterile Teklad 5% stock diet, Harlan,
Madison, WI) and water (via an automated watering sys-
tem) were provided ad libitum. Light–dark cycle (12 hr)
was maintained in the animal room. All protocols were
approved by the Institutional Animal Care and Use
Committee at the University of Iowa.
Animals without restraint were exposed by inhalation
for 4 hr/day, 5 days/wk for period of 2 wks in the sub-
acute study and for 13 wks in the sub-chronic study. In
both studies, mice were necropsied either within one hr
(0 wk) or 3 wks after (3 wks) the last exposure. During
the 3 wk period post exposure, animals remained in the
vivarium without exposure. Both studies also included
sentinel mice that were housed in the vivarium during
the whole duration of each study. The average mass con-
centration of ZnO NPs in the whole-body chamber in
sub-acute study was 3.6 ± 0.5 mg/m3 (mean ± standard
deviation) and in the sub-chronic study was 3.3 ±
0.6 mg/m3. Control animals (shams) were exposed to
HEPA-filtered laboratory air in the identical exposure
chamber in an adjacent laboratory. We estimated cumu-
lative doses of 51 and 306 μg/mouse (in sub-acute and
sub-chronic study, respectively) assuming a minute vol-
ume of 25 mL/min and a deposition fraction of 0.24 in
the tracheobronchial and pulmonary region. Deposition
fraction was based on a rat computational fluid dynamic
model [31] and an average particle size (40 nm) as mea-
sured by a scanning mobility particle sizer (SMPS).
Generation of aerosol and inhalation exposure of mice
Mice in this study were exposed in a whole-body expos-
ure chamber, as previously described [32]. ZnO aerosols
were generated from a suspension of ZnO NPs in water
(Optima grade, Fisher Scientific, Pittsburgh, PA) from a
liquid concentration of 1 mg ZnO NPs/mL using a 6-jet
Collison nebulizer (BGI Inc. Waltham, MA) supplied
with filtered pressurized air. To minimize agglomeration,
a suspension of ZnO NPs in water was prepared freshly
each day and ultra-sonicated (continuous sonication)
with a high frequency probe set at 30% of the maximum
amplitude at 20 kHz (model 550, Fisher Scientific,
Pittsburgh, PA) for 20 minutes before it was placed into
the nebulizer. Most of our practices for ultrasonic dis-
persion of NP suspension were in an agreement with
recommendations by Taurozzi et al. [33]. A magnetic
stir bar was placed into the nebulizer to facilitate stirring
of the ZnO suspension during nebulization. Aerosol
generated by the nebulizer passed through a brass drying
column heated to 110°C (to evaporate water droplets) as
well as a tube containing a 20 mCi 63Ni source (to re-
move static charge) prior to entering the chamber.
To assess the size distribution of generated ZnO NP
aerosol during animal exposure, the air from the cham-
ber was sampled at flow 1 L/min using an SMPS (TSI
Inc., Shoreview, MN, model 3036 with model 3081 long-
differential analyzer and model 3785 water-based con-
densation particle counter, measuring particle diameters
in 105 size channels between 7.4 - 289 nm). Geometric
mean (GM) mobility diameter and geometric standard
deviation (GSD) of aerosol sizes in individual exposures
were calculated.
Mass concentration of the aerosol in the whole-body
chamber was measured gravimetrically using 47-mm
fiberglass filters (Whatman, Middlesex, UK) held in
stainless steel holders placed in line with the exhaust air
flow (24 L/min). Filters were pre- and post-weighed
using a calibrated Mettler MT5 six-place balance
(Mettler-Toledo, Inc., Columbus, OH) placed in a dedi-
cated climate-controlled room and were changed every
two hours. Generated aerosol in the chamber was
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collected on nickel grids placed inside the exposure
chamber or using an electrostatic precipitator (Model
100, ESP Nano Inc., Spokane WA).
Bronchoalveolar lavage fluid and blood analyses
Euthanasia of mice was performed by overdose of iso-
flurane followed by cervical dislocation and exsanguin-
ation through the heart. The lungs (n = 6 in each
experimental group) were lavaged, in situ, 3 times with
approximately 1 mL of 0.9% sterile sodium chloride so-
lution (Baxter, Deerfield, IL), the recovered bronchoalve-
olar lavage (BAL) fluid was centrifuged (800 × g, 5 min),
the cell pellet was used for enumeration of total and
differential cell counts. The lavage supernatants were
stored at -80°C for later analyses of total protein
using Bradford protein assay (Bio-Rad Laboratories, Inc.,
Hercules, CA), LDH activity (Roche Diagnostics, Penzberg,
Germany) and cytokine levels measured by multiplexed
fluorescent bead-based immunoassays (Bio-Plex Pro Mouse
Cytokine, Chemokine, and Growth Factor Multiplex As-
says, Bio-Rad Laboratories, Inc., Hercules, CA). Measured
cytokines in both studies included: interleukin (IL)-6, IL-12
(p40), tumor necrosis factor (TNF)-α, granulocyte macro-
phage colony stimulating factor (GM-CSF), keratinocyte-
derived cytokine (KC), monocyte chemotactic protein
(MCP)-1, and macrophage inflammatory protein (MIP)-1α.
In sub-chronic study, we also measured IL-4, IL-5, IL-13
and IL-17. Blood samples for analyses of hematology pa-
rameters (n = 6 in each group) were collected by cardiac
puncture into tubes containing EDTA (Multivette®, SAR-
STEDT AG & Co., Nümbrecht, Germany) and analyzed
using an automated hematology analyzer (Sysmex XT-
2100, Kobe, Japan).
Lipid peroxidation assay
To investigate the ZnO NP-mediated generation of ROS
after sub-chronic exposure to ZnO NPs, malondialde-
hyde (MDA, product of lipid peroxidation) levels were
measured in lung tissue homogenates (n = 6) using the
thiobarbituric acid reactive substances (TBARS) assay kit
(Cayman Chemical Company, Ann Arbor, MI) following
the manufacturer’s protocol.
ICP-MS elemental analysis of BAL fluid and organs
Cell-free BAL supernatants were centrifuged at 44,900 ×
g for 30 min and Zn2+ concentrations were determined.
Lung, liver, spleen, kidney, heart and brain tissues from
mice in each group were stored at −80°C immediately
after resection. Tissues were lyophilized for 16 hr at 0.13
mBar and −50°C in a freeze dryer (Labconco Corp.,
Kansas City, MO) and then weighed. The tissues were
digested in a HotBlock™ digestion system (Environmen-
tal Express, Mt. Pleasant, SC) at 95-98°C using mixtures
of high purity concentrated hydrochloric acid and nitric
acid (Fisher Optima® grade) in 1:3 ratio, respectively.
Metal analysis of the digested tissues, blood and BAL
fluid was performed using inductively coupled plasma
mass spectrometer (Xseries 2 quadrupole ICP-MS,
Thermo Fisher Scientific Inc., West Palm Beach, FL)
with a method detection limit for Zn of less than 1 μg/kg.
Each sample was spiked with cobalt as an internal
standard at 20 μg/L.
Pulmonary mechanics measurements
Airway hyper-reactivity to methacholine challenge in
mice after exposure to ZnO nanoparticle aerosol (n = 6
in sub-acute study, n = 8 at 0 wk and n = 3 at 3 wks post
exposure in sub-chronic study) was assessed using a
forced oscillation technique in the FlexiVent system
(SCIREQ, Montreal, QC, Canada). Anesthesia was in-
duced by intraperitoneal administration of 90 mg/kg of
pentobarbital sodium (Ovation Pharmaceuticals, Inc.
Deerfield, IL, USA). The trachea was exposed and
tracheotomy performed using a tracheal cannula with
luer adapter (1.3 mm, length 20 mm, Harvard Appar-
atus, Holliston, MA, USA). The cannula was connected
to a computer-controlled small animal ventilator set at a
frequency of 150 breaths/min, a tidal volume of 10 mL/
kg, and a positive end-expiratory pressure of 2 to 3 cm
H2O. After measurement of a baseline, each mouse was
challenged with increasing concentrations of methacho-
line aerosol (1, 3, 10, and 30 mg/mL) that were gener-
ated for 10 s with an in-line nebulizer directly through
the canulated trachea. Dynamic resistance (R) and dy-
namic compliance (C) were measured using a “snapshot”
protocol each 20 s for 5 min, ensuring that measured pa-
rameters stabilized. The mean of these 15 values was
calculated for each methacholine dose. After each dose,
the lungs were inflated to total lung capacity to return
the measurements to baseline.
Histopathology of lung tissues
Mice that were not lavaged (n = 5 and n = 6 in sub-acute
and sub-chronic study, respectively) were perfused through
the heart with saline and lungs were fixed in 10% buffered
formalin via the cannulated trachea. The tissues were
paraffin-embedded, sectioned at 5 μm, and stained with
hematoxylin and eosin (H&E). Tissue sections were eval-
uated by a board-certified veterinary pathologist using
light microscopy with the focus on parenchymal archi-
tecture (bronchioles, alveoli, pleura, and vasculature),
and presence or absence of inflammatory cell infiltrates,
evidence of acute lung injury, lymphoid agglomerates or
fibrosis. We also evaluated BAL cells and lung tissues
using dark field microscopy as well as TEM equipped
with an energy dispersive spectrometer (EDS), as de-
scribed previously [28].
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Statistical analyses
Outcome measures from mice exposed to ZnO NPs and
control mice exposed to filtered laboratory air were ana-
lyzed using one-way analyses of variance (ANOVA)
followed by Tukey test (Sigma Plot v.11.0, Systat Soft-
ware Inc., Point Richmond, CA). If data were not nor-
mally distributed, Kruskal-Wallis ANOVA on Ranks was
used. A p-value less than 0.05 was considered statisti-
cally significant. Data are expressed as mean ± standard
error (SE) unless otherwise noted.
Results
ZnO nanoparticle characterization
The XRD pattern for the ZnO NPs are compared to
standard crystalline zincite in Figure 1A. These data
show that the nanoparticles have the same crystal struc-
ture as that of bulk zincite. Figure 1B shows a TEM
image of nanoparticle agglomerates deposited on a TEM
grid from a methanol solution. The diameters of individ-
ual particles were assessed by measurement of over 400
particles and yielded a primary particle size distribution
of 15 ± 4 nm and 26 ± 11 nm for the two lots of NPs
used in sub-acute and sub-chronic study, respectively
(Figure 1C and Table 1).
The specific surface area of the sample was calculated
in the nitrogen relative pressure range from 0.05 to 0.3
where the BET isotherm is most linear. This yielded a
surface area of 47 ± 1 m2/g for ZnO NPs for the batch of
NPs used in sub-acute study and 15 ± 4 m2/g for the
batch used in sub-chronic study. Surface composition
examination using ATR-FTIR spectroscopy (Figure 2A)
revealed that carbonates are present on the nanoparticle
surface. XPS was also used to characterize the surface
composition of the ZnO NPs. High resolution XPS spec-
tra (Figures 2B) show binding energy peaks in the
Zn 2p, C 1s, and O 1s regions of the photoelectron
spectrum. The Zn 2p peaks at 1021.1 eV and 1044.4 eV
(Figure 2B) can be assigned to Zn2+ in ZnO crystal [34].
The O 1s peak positions at 530 eV and 531.5 eV
(Figure 2B) correspond to surface and near surface oxy-
gen in crystal lattice and O–H groups on the surface
[35]. The C 1s region has three peaks (Figure 2). The
peak at 285.0 eV is due to adventitious carbon on the
nanoparticle surfaces. Two species, C–OH (hydroxyl)
and C–O–C (ether), can contribute to the 286.4 eV peak
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Figure 1 Characterization of the phase and size of ZnO nanoparticles. A. XRD spectrum pattern of the nanoparticles (black) compared to
XRD spectrum of reference material, zincite (red lines). B. TEM image of ZnO nanoparticles deposited onto a TEM grid from a methanol solution.
C. Particle size distribution determined from TEM.
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[36] and the peak at 289.6 eV is due to O–C–O (carbon-
ate) [37].
Dissolution of ZnO in artificial lung fluids
Dissolution is a surface phenomenon and the propensity
of ZnO nanoparticles to dissolve into ions was investi-
gated. As shown in Figure 3, less than 1% of ZnO dis-
solved in Gamble’s buffer after 2 wks. In contrast, 100%
of the ZnO dissolved within the first 24 hr of mixing in
ALF solution. ALF buffer contains 0.11 M concentration
of citric acid, which simulates in vivo protein binding.
Thus this result agrees with what is known about citric
acid and the ability for it to adsorb to the surface
thereby promoting dissolution of ZnO [23]. Gamble’s so-
lution contains a much smaller amount of sodium citrate
(0.4 mM) and a complex mixture of other anions and
cations that could prevent NPs from releasing Zn2+, or
could trap the released ions if other precipitates form.
The presence of a significant amount of citrate ions
(or protein binding) affects the fate and possible toxic
effect of this nanomaterialas has been extensively dis-
cussed in the literature [38]. This should be taken into
account when evaluating the toxicity of ZnO NPs.
Aerosol characterization
ZnO nanoparticle aerosols collected in the exposure
chamber were imaged using TEM and size distributions
were measured using a SMPS (Figure 4). It can be seen
that these substrate-collected aerosols contain primary
particles of ZnO that are aggregated to form the larger
aerosol. The aerosol size distribution measured in the
whole-body inhalation chamber yielded a geometric mean
mobility diameter of 46 nm (GSD= 1.8) and 36 nm (GSD
= 1.8) in sub-acute and sub-chronic studies, respectively
Table 1 Summary of physicochemical properties of ZnO
NPs and generated aerosol
ZnO NPs
Primary particle size1 15 ± 4 nm (26 ± 11 nm)#
Crystalline or amorphous Crystalline, zincite
Surface functionality CO3
2−, OH−, CH
BET surface area2 47 ± 1 m2/g (15 ± 4 m2/g)#
Nanoparticle dissolution Gamble’s solution (pH 7.4): < 1%
ALF* (pH 4.5): 100%
Aerosol characterization in the whole-body exposure chamber:
Sub-acute study Sub-chronic study
Aerosol size distribution3 GM = 46 nm GM= 36 nm
GSD = 1.8 GSD = 1.8
Exposure mass concentration2 3.6 ± 0.5 mg/m3 3.3 ± 0.6 mg/m3
1Primary diameter as measured by TEM in our laboratory ± standard deviation
(SD), 2Mean ± standard deviation, 3GM: Geometric mean mobility diameter and
GSD: geometric standard deviation, #Analysis of ZnO NPs used in sub-chronic
study in parenthesis. *ALF: artificial lysosomal fluid.
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Figure 2 Characterization of surface composition for commercially
manufactured ZnO NPs using spectroscopic probes. A. ATR-FTIR
spectra of ZnO NPs compared to ZnCO3 in the 1200 t0 1600 cm
−1 re-
gion. B. High resolution XPS data of ZnO NPs in the Zn 2p, O 1s and C
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(Table 1). These measurements show that the mice were
exposed to aggregates in the nanoscale regime below
100 nm. TEM-EDS analyses of particles deposited on the
grids placed in the exposure chamber confirmed the pres-
ence of elemental Zn (data not shown).
Dosimetry of ZnO NPs in the blood, BAL fluid and
selected tissues
In the sub-acute study, Zn lung concentrations mea-
sured by ICP-MS were significantly (p < 0.02) higher in
mice necropsied immediately (0 wk) after the exposure
(144.8 ± 6.9 μg/g lung (dry wt)) than in sham-exposed
mice (123.3 ± 2.6 μg/g lung (dry wt)). Concentration of
Zn in the lungs of mice necropsied after the 3-wk rest
period (3 wks) post exposure was 131.4 ± 13.7 μg/g lung
(dry wt) (Table 2 ). Zn2+ concentrations in BAL fluid
were significantly (p < 0.001) elevated immediately after
the exposure (73 ± 9 μg/L) compared to sham-exposed
(16 ± 2 μg/L) and mice rested for 3 wks (16 ± 2 μg/L)
(Table 2). Blood, liver, spleen, kidney, heart and brain
did not show any significant increase of Zn concentra-
tion with the exposure.
In the sub-chronic study, Zn concentrations in BAL
fluid, blood, spleen, and kidneys were elevated in the
group sacrificed immediately post exposure compared to
controls, but this increase was not statistically significant
(Table 2). Zinc in hearts in the group at 0 wk post ex-
posure was significantly (p < 0.05) increased compared to
shams. Concentrations in other major organs did not
differ from sham-exposed mice.
Animal weight gain
We observed a body weight loss in mice (average of 2 g)
after the first week of exposure in the sub-chronic ZnO
NP study (Figure 5). This drop was not observed in the
sub-acute study, in which mice gained 0.6 g after the
first week of exposure. Animals exposed to laboratory
air and sentinels gained 0.8 g and 0.9 g, respectively.
Evaluation of BAL fluid and hematology parameters
Sub-acute study
The number of total cells in BAL fluid (Table 3) was sig-
nificantly (p < 0.01) increased in mice exposed to ZnO
NPs and necropsied at 0 wk post exposure (150.3 ± 14.9
× 103 cells/mouse) as compared to control mice (92.7 ±
8.6 × 103 cells/mouse). Similarly, as shown in Figure 6A,
the number of macrophages (144.3 ± 11.8 × 103 cells/
mouse) was significantly (p < 0.01) increased compared
to shams (92.5 ± 8.6 x 103 cells/mouse). Mice necropsied
at 0 wk post exposure had significantly higher (p < 0.02)
recruitment of neutrophils (2.6 ± 0.7 × 103 cells/mouse)
as compared to shams (0.1 ± 0.07 × 103 cells/mouse).
However, the proportion of neutrophils among total cells
was only 1.7% in mice necropsied at 0 wk.
Concentrations of total protein analyzed in BAL fluid
were not different between ZnO NP-exposed groups and
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Figure 4 Particle size distributions of generetated ZnO aerosol
measured by SMPS in sub-acute and sub-chronic studies.
Table 2 Zn concentration in BAL fluid and organs of shams and ZnO NP-exposed mice determined by ICP-MS
Sub-acute study Sub-chronic study
Zn concentration Experimental group: Experimental group:
Shams
(n = 6)
ZnO 0 wk
(n = 7)
ZnO 3 wks
(n = 6)
Shams
(n = 6)
ZnO 0 wk
(n = 8)
ZnO 3 wks
(n = 6)
BAL fluid, μg/L # 16 ± 2 73 ± 9*** 16 ± 2 48 ± 10 80 ± 23 42 ± 1
Blood, μg/L 4800 ± 123 4650 ± 131 4840 ± 157 5117 ± 189 5567 ± 42 4950 ± 250 ##
Lung, μg/g (dry wt) 123.3 ± 2.6 144.8 ± 6.9** 131.4 ± 13.7 109.7 ± 8.8 102.1 ± 4.4 109.6 ± 4.3
Heart, μg/g (dry wt) 121.8 ± 2.7 127.8 ± 6.0 112.6 ± 10.1 115.4 ± 4.4 150.9 ± 14.7* 124.1 ± 7.0
Liver, μg/g (dry wt) 155.5 ± 5.5 161.3 ± 4.4 153.2 ± 10.4 100.2 ± 5.3 111.2 ± 6.0 108.9 ± 8.4
Spleen, μg/g (dry wt) 108.6 ± 2.5 114.6 ± 4.2 111.6 ± 3.9 164.9 ± 33.6 277.6 ± 46.2 156.0 ± 23.3
Kidney, μg/g (dry wt) 97.8 ± 8.4 88.0 ± 4.0 85.9 ± 5.8 96.8 ± 7.9 110.8 ± 9.9 97.2 ± 7.0
Brain, μg/g (dry wt) 101.7 ± 4.4 102.7 ± 4.1 104.7 ± 4.1 47.9 ± 3.6 43.6 ± 2.6 43.6 ± 2.7
Values are expressed as mean and SE; *p < 0.05, **p < 0.05, ***p < 0.001 significantly increased from shams.
# BAL was not digested, Zn concentration represents mainly dissolved Zn ions in BAL fluid.
## n = 3.
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controls. The activity of LDH was not different between
mice necropsied at 0 wk and shams but was significantly
higher 3 wks post exposure (p < 0.01, Table 3).
Only 2 of the 7 measured inflammatory cytokines/che-
mokines were significantly elevated at 0 wk post exposure,
IL-12p(40) and MIP-1α (p < 0.05 and p < 0.01, respect-
ively). These concentrations were increased 1.6- and 1.3-
fold from levels in sham-exposed mice (Figure 7A).
Hematology parameters were evaluated to assess if expo-
sure to ZnO NPs caused any systemic inflammatory
changes (Table 4). We found no significant differences be-
tween ZnO NP-exposed mice and shams, with the excep-
tion of hematocrit that was significantly higher in mice
exposed to ZnO NPs and necropsied 3 wks post exposure
compared to shams (52.7% vs. 47.7%, respectively).
Sub-chronic study
There was a significant enhancement in the recruitment
of cells to the lungs after sub-chronic exposure to ZnO
NPs compared to sham-exposed mice. Mice euthanized
immediately after the last ZnO NP exposure had a
2-fold higher number of cells in BAL fluid than shams
(Table 5). This increased cellularity was represented
mainly by macrophages, and there were no significant
increases in numbers of neutrophils or lymphocytes be-
tween ZnO NP-exposed mice and their sham-exposed
counterparts (Figure 6B). The concentration of total pro-
tein and activity of LDH in BAL fluid were not different
between ZnO NP-exposed mice and their controls
(Table 6). In the sub-chronic study we also measured the
concentration of MDA in homogenates of lung tissue as
a marker of ROS generation and found no significant
difference between exposed and control mice. Whole
blood parameters did not show any sign of systemic in-
flammatory response (Table 6). Similarly like in sub-
acute study, hematocrit in mice exposed for 13 wks
sacrificed at 3 wks post exposure was increased. Cyto-
kine/chemokine concentrations in BAL fluid for the sub-
chronic study are shown in Figure 7B. The results show
no significant differences in ZnO NP-exposed groups
and shams. The concentrations of IL-4 and IL-5 were
below lowest limit of detection (2.20 pg/mL and 5.38
pg/mL, respectively).
Lung histopathology in sub-acute and sub-chronic study
Since a preliminary bright field microscopy screening
of lung tissues with H&E staining showed a lack of
evidence for overt lesions, a more sensitive scale for the
detection of changes in pathologic parameters (inflam-
mation, cell injury, fibrosis, congestion and possible eosi-
nophila) was imposed. Due to application of this 4-point
scale (0 - no lesion, 1 - minor focal change [<10% of
lung], 2 – multifocal to coalescing inflammation
[11-50%], and 3 – widespread > 50%), even the control
animals showed presence of many evaluated histology
parameters, indicating that the extent of lesions found in
exposed animals was not due to ZnO NP exposure. In
both, the sub-acute and sub-chronic study, there were a
few lungs that showed a slight increase in number of
macrophages and/or with occasional evidence of alveolar
macrophage activation (slightly foamy cytoplasm, karyo-
megaly, binucleate, and mitotic figures). In addition to
these changes, rare minor foci of perivascular lymphoid
cells and/or focal septal hypercellularity were found in
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Figure 5 Body weights of animals during sub-chronic exposure
to ZnO NPs. There was a significant decline in the body weights of
mice on day 5 of ZnO NP exposure, compared to controls
or sentinels.
Table 3 Total number of cells, total protein concentration and activity of LDH in BAL fluid in shams and ZnO
NP-exposed mice (sub-acute study)
Sub-acute study Experimental group:
Parameter in BAL fluid Sentinels Shams ZnO ZnO
(n = 2) 0 wk 0 wk 3 wks
(n = 6) (n = 6) (n = 6)
Total cells/mouse, n × 103 105.0 ± 27.0 92.7 ± 8.6 150.3 ± 14.9** 67.0 ± 11.2
Total protein, μg/mL 122.2 ± 2.9 135.5 ± 6.8 125.5 ± 4.1 131.3 ± 5.8
LDH activity, U/L 63 ± 18 46 ± 4 32 ± 9 93 ± 23**
Values are expressed as mean and SE; **p < 0.01 significantly different from sham-exposed animals (one way ANOVA).
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sub-chronic study mice. There was a distinct lack of cell
injury, fibrosis or eosinophil infiltration in mice from ei-
ther study. In the few sites with hypercellularity of the
alveolar septa, there were occasional granulocytes par-
tially sequestered in the septa composed of both neutro-
phils and eosinophils, however these were just marginal
inside of sticky capillaries due to minor focal activation.
Figure 8A shows the histopathology scores from the
lung tissues. Most common minor changes found in
lung tissues of controls or ZnO NP-exposed mice are
shown in Figures 8B, C and D.
Pulmonary mechanics measurements in sub-acute and
sub-chronic study
Measurements of pulmonary mechanics involving resist-
ance and compliance without cholinergic agonist showed
no difference between mice exposed to ZnO NPs and
shams-exposed mice (Figure 9). Treatment with escalat-
ing doses of methacholine showed no evidence of hyper-
reactive airways due to exposure to ZnO NPs. For
comparison, positive control mice treated with bleo-
mycin via intra-tracheal instillation (to induce transient
fibrosis) or mice sensitized and challenged with house
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Figure 6 Number of differential cells in BAL fluid in controls and animals exposed to ZnO NPs for period of 2 (A) or 13 wks (B). In both
studies there was a significant increase in number of macrophages in BAL fluid, in comparison with shams necropsied at the same time after
exposure. The number of neutrophils was significantly increased only in sub-acute study, however biologically this increase was just marginal.
Data are expressed as mean ± SE.
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Figure 7 Concentration of selected cytokines/chemokines in BAL fluid of mice exposed sub-acutely (A) or sub-chronicly (B) to ZnO
NPs. Data are expressed as mean ± SE; *p < 0.05, **p < 0.01 significantly different from shams.
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dust mite allergen (Dermatophagoides pteronyssinus, Der
p 2) demonstrated increasing resistance and decreasing
compliance with increasing doses of inhaled methacho-
line. We conclude that inhalation exposure to ZnO NPs
for period of 2 or 13 wks did not cause clinically signifi-
cant remodeling of the airway in mice nor did it induce
hyperreactive airways.
Discussion
Our studies assessed toxicological effects of ZnO NPs
in mice following sub-acute (2-wk) and sub-chronic
(13-wk) inhalation exposure. Nanoparticles were fully
characterized prior to and during exposures. Geometric
mean mobility diameter of ZnO NP aerosol sampled
from the whole-body chamber was 46 nm and 36 nm in
sub-acute and sub-chronic study, respectively and dem-
onstrated a moderate degree of aggregation.
The bioavailability and toxicity of metal oxide nano-
particles are often related to the ability of the nanoparti-
cles to deliver soluble metal ions to the adjacent tissues
[22]. Nanoparticles often have enhanced dissolution kin-
etics due to their larger surface area in comparison with
bulk material [23]. Additionally, the extent of dissolution
can be size dependent [23]. Multiple studies have shown
that ZnO NPs dissolve in the acidic environment of
the phagolysosomes [22,26]. Here, we observed ligand-
promoted dissolution [39] facilitated by citrate ligands
used in ALF solution to represent a coordinating moiety
that might be found in protein binding as well (Figure 3).
Our data suggest that ZnO NPs dissolved in the lung
(Table 2). Concentration of Zn2+ in the supernatants of
BAL fluid was 4.5-fold higher in mice necropsied imme-
diately after the exposure than in shams or mice necrop-
sied 3 wks post exposure (Table 2). For the sub-chronic
study (Table 2), the increase of Zn2+ ions in BAL fluid
from shams was lower, the concentration was only
2-fold higher than in shams or mice at 3 wks post
exposure. However, this increase was not statistically
significant (p = 0.065). Interestingly, in the sub-chronic
study, we did not find any increase in Zn in the lungs of
mice sacrificed at 0 wk in comparison with controls.
Evaluation of BAL cells and lung tissues using dark field
microscopy as well as TEM-EDS did not show a distinct
presence of Zn NPs inside the macrophages or lung tis-
sues (data not shown). The blood Zn concentrations
were slightly elevated in mice at 0 wk in sub-chronic
study, but not in sub-acute study. Since we have used
a whole-body exposure chamber in our studies, it is
possible that some portion of ZnO particles was inges-
ted and transferred to the blood through the gastro-
intestinal system. None of the other organs analyzed in
either study had significantly elevated Zn concentrations.
Wang et al. performed an acute instillation study in
Wistar rats in which a bolus of 2.5 mg/kg ZnO NPs was
delivered by a dry powder sprayer directly into nasal
passages, twice daily for 3 days (total dose 15 mg/kg)
[10]. Doses in our studies were lower with 2.0 mg/kg de-
livered in 14 days (sub-acute) and 10.9 mg/kg delivered
in 89 days (sub-chronic). Even at this high dose, Wang
et al. found no significant differences in Zn content in
lungs compared to controls, Zn levels were significantly
Table 4 Blood parameters in shams and mice after
sub-acute exposure to ZnO NPs
Sub-acute study Experimental group:
Whole blood parameter Shams ZnO 0 wk ZnO 3 wks
WBC × 103/μL 2.91 ± 0.9 2.81 ± 0.3 3.11 ± 0.4
RBC × 106/μL 9.85 ± 0.3 10.27 ± 0.5 9.49 ± 0.2
Hemoglobin, g/dL 16.5 ± 0.4 17.3 ± 0.6 15.3 ± 0.2
Hematocrit,% 47.7 ± 1.3 51.3 ± 2.0 52.7 ± 1.1**
Monocytes × 103/μL 0.33 ± 0.1 0.33 ± 0.0 0.39 ± 0.1
Neutrophils × 103/μL 0.56 ± 0.1 0.38 ± 0.1 0.84 ± 0.1
Lymphocytes × 103/μL 1.95 ± 0.7 2.02 ± 0.3 1.83 ± 0.3
Eosinophils × 103/μL 0.052 ± 0.016 0.052 ± 0.016 0.082 ± 0.019
Basophils × 103/μL 0.014 ± 0.008 0.022 ± 0.009 0.018 ± 0.007
Values are expressed as mean and SE, WBC - white blood cells, RBC - red
blood cells; **p < 0.02 (significantly different from shams), n = 6 in each group.
Table 5 Total number of cells, total protein concentration and activity of LDH in BAL fluid and MDA concentration in
the lungs in shams and ZnO NP-exposed mice (sub-chronic study)
Sub-chronic study Experimental group:
Sentinels Shams ZnO Shams ZnO
0 wk 0 wk 3 wks 3 wks
Parameter in BAL fluid (n = 6):
Total cells/mouse, n × 103 137.3 ± 20.5 156.0 ± 11.8 302.0 ± 11.5*** 116.3 ± 8.3 188.0 ± 19.3**
Total protein, μg/mL 101.7 ± 3.0 101.8 ± 2.4 108.4 ± 5.5 117.5 ± 16.2 123.8 ± 6.6
LDH activity, U/L 106.0 ± 19.5 60.8 ± 14.6 74.7 ± 12.7 95.3 ± 12.1 83.7 ± 14.5
Parameter in Lung (n = 6):
MDA concentration, nmol/mL NA 50.0 ± 2.5 58.7 ± 6.8 NA NA
Values are expressed as mean and SE; ***p < 0.001, **p < 0.01 significantly different from control counterparts (one way ANOVA followed by Tukey test);
NA not analyzed.
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Table 6 Blood parameters in shams and mice after sub-chronic exposure to ZnO NPs
Whole blood
parameter
Experimental group:
Sentinels Shams 0 wk ZnO 0 wk ZnO 3 wks
WBC × 103/μL 3.62 ± 0.5 4.18 ± 0.6 3.79 ± 1.0 4.90 ± 0.4
RBC × 106/μL 9.66 ± 0.2 9.20 ± 0.2 9.6 ± 0.4 9.63 ± 0.3
Hemoglobin, g/dL 15.4 ± 0.2 16.0 ± 0.2 16.2 ± 0.4 16.2 ± 0.2
Hematocrit,% 50.2 ± 0.7 45.0 ± 0.6 47.8 ± 0.3 52.9 ± 1.7
Monocytes × 103/μL 0.34 ± 0.1 0.22 ± 0.1 0.24 ± 0.1 0.20 ± 0.3
Neutrophils × 103/μL 2.11 ± 0.5 0.92 ± 0.2 1.29 ± 0.3 1.9 ± 0.2
Lymphocytes × 103/μL 1.14 ± 0.2 2.98 ± 0.4 2.20 ± 0.9 2.75 ± 0.4
Eosinophils × 103/μL 0.032 ± 0.010 0.055 ± 0.013 0.062 ± 0.035 0.074 ± 0.013
Basophils × 103/μL 0.002 ± 0.001 0.013 ± 0.003 0.013 ± 0.004 0.008 ± 0.003
Values are expressed as mean and SE, WBC - white blood cells, RBC - red blood cells, n = 6 in each group.
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Figure 8 Qualitative histopathological evaluation and micrographs of lung tissues of mice exposed to ZnO NPs. Histopathologic evaluation
(focusing on inflammation, cell injury, congestion, fibrosis and eosinophilia) was performed by light microscopy using a semi-quantitative 4-point scale:
0 - no lesion, 1 - minor focal change (<10% of lung), 2 – multifocal to coalescing inflammation (11-50%), and 3 – widespread > 50% (A). Micrographs
of lung tissues showing most common minor changes: focal perivascular lymphoid cells (40x, B), focal accumulation of mononuclear cells (40x, C),
and minor perivascular lymphoid cells (20x, D).
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increased in livers at 12 hr and 36 hr time point and
in kidneys at 36 hr time point. Furthermore, they
reported that exposure caused inflammation, interstitial
hyperemia, emphysema and hyperplasia in the lungs and
serious hepatic lesions. These data further suggest that
ZnO NPs dissolve in the lungs or translocate to the
blood for circulation. Intravenously administered ZnO
NPs exhibited a primary retention in lung for the first
hour and were excreted via intestines into feces within
24 h [40]. Such fast elimination of ZnO NPs from the
system might be attributed to a high dissolution of these
particles in biological fluids with lower pH as shown in
Figure 3. The NIEHS Nano GO Consortium found ZnO
NPs to be the most cytotoxic in in vitro studies (out of
three forms of TiO2, and three forms of multiwalled car-
bon nanotubes [MWCNTs] [41]. Unfortunately, ZnO
NPs were not included in their in vivo interlaboratory
evaluation and hence provide no basis for comparison
with this study [42].
ZnO dissolution is relevant to pulmonary toxicity due
to inhalation exposure to ZnO in the welding fumes in
occupational settings [43] as well as for use of ZnO as a
raw material in manufacturing. Inhalation of ultrafine
ZnO was found to be the major cause of zinc fume fever
that is characterized by increased neutrophils in BAL
fluid, along with an increase in TNF-α, IL-1, and IL-8,
followed by decreased lung function, cough, fever, and
metallic taste [43]. The National Institute for Occupa-
tional Safety and Health (NIOSH) has established a rec-
ommended exposure limit for ZnO of 5 mg/m3 as a
time-weighted average concentration for up to a 10-hr
workday and a 40-hr workweek. The estimated doses of
ZnO NPs in tracheobronchial and pulmonary region of
mouse were 51 μg/mouse (2.0 mg/kg) in the sub-acute
and 306 μg/mouse (10.9 mg/kg) in the sub-chronic study.
These estimated doses correspond to the lung dose accu-
mulated by a 70 kg person exposed to a concentration of
5 mg/m3 for 13 or 71 workdays (assuming breathing fre-
quency 15 breaths/min, 600 mL/breath, and pulmonary
deposition fraction for 40 nm particles of 0.5 [31].
Our previous toxicity studies of copper, iron or silver
NPs [28,29,44] are in agreement with “the higher
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Figure 9 Results of pulmonary mechanics measurements of mice after sub-acute (A) or sub-chronic (B) exposure to ZnO NPs or filtered
laboratory air (sham). Resistance and compliance were measured after inhalation challenge to increasing concentration of methacholine (1, 3, 10,
and 30 mg/mL). Plot B also shows resistance and compliance in positive control mice exposed by nasal instillation to bleomycin (fibrosis model) or
house dust mite allergen (Dermatophagoides pteronyssinus, asthma model). No changes in pulmonary mechanics were observed in mice exposed to
ZnO NPs for 2 (A) or 13 wks (B).
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solubility - the higher toxicity effect” [11,45]; however
ZnO NPs despite very high solubility in acidic milieu
that contain coordinating ligands demonstrated minimal
toxicity in our inhalation studies. Of the many pulmon-
ary biomarkers measured, we observed biologically sig-
nificant increase only in total number of cells in BAL
fluid mainly due to an increase in macrophages and a
moderate increase in IL-12(p40) and MIP-1α in BAL
fluid. Measurements of a cytototoxicity biomarker (activ-
ity of LDH) in BAL fluid showed a significant increase in
mice sacrificed at 3 wks post sub-chronic exposure com-
pared to controls. ROS in the lungs (assessed via MDA)
were not different in ZnO NP-exposed mice and con-
trols. Histopathology evaluation of lung tissues as well as
pulmonary mechanics measurements revealed no signifi-
cant changes from controls. There were no eosinophils
and few neutrophils found in BAL fluid or lung tissue in
mice after inhalation exposure to ZnO NPs in sub-acute
or sub-chronic exposure. Furthermore, the concentra-
tions of IL-4, IL-5, IL-13 and IL-17 in BAL fluid were
not elevated after exposure to ZnO NPs. Our results are
contrary to data reported by Cho et al. [8,26,46]. Intra-
tracheal instillation of ZnO NPs at a surface area dose of
50 or 150 cm2/rat (corresponding to a mass of 0.5 mg/
kg or 1.4 mg/kg, respectively) caused eosinophilia, prolif-
eration of airway epithelial cells, goblet cell hyperplasia,
and pulmonary fibrosis. This eosinophilic response in
BAL fluid was not reproduced in mice (C57Bl/6 and
BALB/c) after an aspiration of ZnO NPs dispersed in 5%
heat-inactivated mouse serum (15 cm2/mouse or 1.2 mg/
kg), but these authors reported that the concentration of
eotaxin and IL-13 in the BAL fluid was significantly in-
creased at 24 hr post exposure compared to controls [26].
Later studies by this group found that recruitment of
eosinophils was initiated by metal oxide nanoparticles
themselves not their soluble ions [46]. To assess this dis-
crepancy, we exposed mice to ZnO NPs by intra-tracheal
instillation (4 mg/kg or 47 cm2/mouse) with necropsy
24 hr after the exposure and found a higher recruitment
of neutrophils (40%) in BAL fluid (data not shown) than
in shams (2%) in which no eosinophils were found. The
recruitment of neutrophils to the lungs in case of instilla-
tion exposure might be a part of an acute inflammatory
response to a different exposure method (instillation vs.
inhalation). Our studies confirm that ZnO NPs have very
modest inflammatory potency in vivo after repeated inhal-
ation exposures but one time instillation exposure of a
bolus dose of NPs caused an inflammatory response.
These results support the notion that in vitro ZnO NP
studies in submersed condition may produce false-positive
results due to a higher dissolution of ZnO NPs in media
without further translocation and clearance. Furthermore,
Cho et al. [26] observed that large poorly dispersed ag-
glomerates of ZnO NPs induced lower eosinophilia (1%)
compared to well-dispersed ZnO NPs (38%) and hypothe-
sized that eosinophilic inflammation might be induced
only by well dispersed ZnO NPs at high doses. We suggest
that inhalation studies at environmentally relevant doses
represent more realistic exposures to ZnO NP aerosols.
In our studies, we found a significant but modest in-
crease in IL-12(p40) as well as MIP-1α compared to
controls after sub-acute exposure to ZnO NPs. Both
cytokines are released by activated macrophages [47].
Histopathology evaluation of lung tissues showed a
moderate presence of slightly foamy alveolar macro-
phages in mice exposed to ZnO NPs necropsied imme-
diately post exposure. On the other hand, this finding
might be important for a possible use of ZnO NPs in an
anti-cancer treatment. It was reported that ZnO NPs in-
duce release of the proinflammatory cytokines (IL-12,
IFN-γ, and TNF-α) without major cytotoxicity effects
[48] and our studies support this potential use.
Development of clinical tolerance to repeated inhal-
ation exposure to ZnO fumes from welding processes
has been reported in clinical studies of metal fume fever
[5] as well as in a study of zinc foundry workers [49]
and a studies of ZnO fumes in mice [6,50]. Symptoms of
metal fume fever usually dissipate within 24–48 hr with-
out major lung injury [43,49]. It is possible that repeated
inhalation exposure to ZnO NPs at low exposure con-
centrations may lead to the attenuation of pulmonary
responses. In our sub-chronic study, we observed a de-
crease in body weight of animals after first 5 days of
exposure to ZnO NPs (Figure 5) which might be a clin-
ical sign of initial response to ZnO NPs that was later di-
minished with repeated exposures. In the pulmonary
tolerance study [6], NIH-Swiss mice were exposed to
1 mg/m3 ZnO for 1, 3, or 5 days, mice acquired toler-
ance to neutrophil recruitment to the lungs, however
tolerance to total protein in BAL fluid was not observed
suggesting persistence of lung injury. Furthermore, a
greater lung pathology was found in mice exposed repeat-
edly to ZnO compared to the ones exposed one time. De-
velopment of pulmonary tolerance to repeated exposure
of inhaled toxicants is not fully understood and more
studies are necessary to confirm this phenomenon.
Conclusions
The results of in vitro and in vivo studies of ZnO NP tox-
icity have been contradictory and thus controversial. Our
sub-acute (2-wk-) and sub-chronic (13-wk-) whole-body
inhalation exposure studies with average ZnO NP concen-
tration of 3.5 mg/m3 induced a significant increase in re-
cruitment of total white blood cells to the lungs that was
represented mainly by increased macrophages and a mod-
erate increase of IL-12 (p40) and MIP-1α. None of the
other inflammatory pulmonary markers measured in BAL
fluid or lungs, histopathology evaluation or changes in
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pulmonary mechanics after methacholine challenge were
significantly different from sham-exposed controls. We
observed slightly elevated hematocrit values at 3 wks post
exposure in both sub-acute and sub-chronic exposure.
Our study suggests a high dissolution of ZnO NPs in lung
tissues and translocation of Zn to the blood circulation.
Furthermore, our study shows that the higher dissolution
of metal-based nanomaterials is not necessarily associated
with higher toxicity upon inhalation exposure as seen here
for ZnO.
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